FDA OK's Silvergate's Epaned; new ped hypertension option
This article was originally published in Scrip
The US FDA has granted Silvergate Pharmaceuticals approval to market Epaned (enalapril maleate) powder for oral solution to treat high blood pressure for patients as young as one month – providing not only a new option for adults who may have difficulty swallowing pills, but also for babies and children with pediatric hypertension.
You may also be interested in...
Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
The latest drug development news and highlights from our FDA Performance Tracker.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.